Precision-targeted therapy to combat antibiotic resistance

Frank J. Hernández

TECNUN - Universidad de Navarra, Spain

Methicillin-Resistant Staphylococcus aureus (MRSA) is a dangerous pathogen responsible for many difficult-to-treat infections that are growing and threat public Health. This project focuses on developing a new treatment that activates only at the infection site, minimizing side effects and maximizing effectiveness.

The project aims to advance this groundbreaking technology through comprehensive studies to support the submission of an Investigational New Drug (IND) application with the ultimate goal of paving the way for human trials and transform MRSA treatment. The research team will develop analytical methods to detect the treatment, conduct pharmacology studies in mice, assess the safety profile, and prepare for regulatory submission. Preliminary data shows that this treatment is highly effective and safe in preclinical models. It targets MRSA infections precisely, reducing the risk of antibiotic resistance and minimizing toxicity.

This innovative approach could revolutionize MRSA treatment by offering a safer and more effective solution. In conclusion, it represents a significant advancement in the fight against antibiotic-resistant infections. By combining precision-targeted delivery with minimized toxicity, this innovative treatment has the potential to improve patient outcomes and contribute to global efforts to combat antimicrobial resistance.

• Markus Zeitlinger, Medical University of Vienna

Therapeutic OligonUCleotides Activated by Nucleases (TOUCAN): Targeted antibiotics for bacterial infections

€995.000,00